ANIK · Anika Therapeutics, Inc. · Webcasts, Transcripts & Audio
One customer — 49% of revenue (nine-months ended September 30, 2026)
“Revenue from the Company’s sole significant customer, DePuy Synthes, formerly Johnson & Johnson MedTech, as a percentage of the Company’s total revenue was 47% and 51% for the three-months ended September 30, 2026, and 2025, respectively, and 49% and 50% for the nine-months ended September 30, 2026, and 2025, respectively.”
One customer — 47% of revenue (three-months ended September 30, 2026)
“Revenue from the Company’s sole significant customer, DePuy Synthes, formerly Johnson & Johnson MedTech, as a percentage of the Company’s total revenue was 47% and 51% for the three-months ended September 30, 2026, and 2025, respectively, and 49% and 50% for the nine-months ended September 30, 2026, and 2025, respectively.”
One customer — 51% of revenue (three-months ended September 30, 2025)
“Revenue from the Company’s sole significant customer, DePuy Synthes, formerly Johnson & Johnson MedTech, as a percentage of the Company’s total revenue was 47% and 51% for the three-months ended September 30, 2026, and 2025, respectively, and 49% and 50% for the nine-months ended September 30, 2026, and 2025, respectively.”
One customer — 50% of revenue (nine-months ended September 30, 2025)
“Revenue from the Company’s sole significant customer, DePuy Synthes, formerly Johnson & Johnson MedTech, as a percentage of the Company’s total revenue was 47% and 51% for the three-months ended September 30, 2026, and 2025, respectively, and 49% and 50% for the nine-months ended September 30, 2026, and 2025, respectively.”
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Anika Therapeutics, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Anika Therapeutics, Inc. (ANIK), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.